Integrated analysis of serum lipid profile for predicting clinical outcomes of patients with malignant biliary tumor

Lejia Sun†, Xin Ji‡, Dongyue Wang‡, Ai Guan‡, Yao Xiao‡, Haifeng Xu‡, Shunda Du‡, Yiyou Xu‡, Haitao Zhao‡, Xin Lu†, Xinting Sang†, Shouxian Zhong†, Huayu Yang†* and Yilei Mao†*

Abstract

Background: Serum lipids were reported to be the prognostic factors of various cancers, but their prognostic value in malignant biliary tumor (MBT) patients remains unclear. Thus we aim to assess and compare prognosis values of different serum lipids, and construct a novel prognostic nomogram based on serum lipids.

Methods: Patients with a confirmed diagnosis of MBT at our institute from 2003 to 2017 were retrospectively reviewed. Prognosis-related factors were identified via univariate and multivariate Cox regression analyses. Then the novel prognostic nomogram and a 3-tier staging system were constructed based on these factors and further compared to the TNM staging system.

Results: A total of 368 patients were included in this study. Seven optimal survival-related factors—TC/HDL > 10.08, apolipoprotein B > 0.9 g/L, lipoprotein> 72 mg/L, lymph node metastasis, radical cure, CA199 > 37 U/mL, and tumor differentiation —were included to construct the prognostic nomogram. The C-indexes in training and validation sets were 0.738 and 0.721, respectively. Besides, ROC curves, calibration plots, and decision curve analysis all suggested favorable discrimination and predictive ability. The nomogram also performed better predictive ability than the TNM system and nomogram without lipid parameters. And the staging system based on nomogram also presented better discriminative ability than TNM system (P < 0.001).

Conclusions: The promising prognostic nomogram based on lipid parameters provided an intuitive method for performing survival prediction and facilitating individualized treatment and was a great complement to the TNM staging system in predicting overall survival.

Keywords: Serum lipid, Prognosis, Biomarker, Nomogram, Malignant biliary tumor

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Malignant biliary tumor (MBT) is amongst the most aggressive gastrointestinal tract tumor and accounts for approximately 4% of all malignancy in the gastrointestinal tract [1]. MBT received considerable attention for its high mortality, poor prognosis and great repercussion on quality of life, with a 5-year overall survival (OS) rate of 25–50% for gallbladder cancer (GBC), 20–40% for intrahepatic cholangiocarcinoma (ICC) and 15–50% for extrahepatic cholangiocarcinoma (ECC) [2, 3]. However, due to the silent clinical manifestations, low specificity of most diagnostic modalities, high invasiveness, early hematogenous and lymphatic metastasis, almost 30–70% of patients are not capable of curative treatment [3–5]. Thus, new prognostic factors with good predictive ability and the prognostic predictive model is needed for early risk stratification of patients’ prognosis as well as identifying potential therapeutic targets, which further facilitate early clinical intervene and individualized treatment.

Tumor staging is essential for MBT because the choice of therapeutic options largely depends on the stage. And inaccurate staging could cause patients to suffer extra injuries or lose their possibility to cure as the surgery is the only potentially curative treatment. Currently, prognostic prediction of MBT mostly based on the AJCC TNM staging system [6], which mainly based on surgical pathology features including tumor size, lymph node metastasis and distant metastasis, regardless of clinical and laboratory parameters. Previous studies also proposed several staging systems including clinical parameters such as hemoglobin, alkaline phosphatase and C reactive protein, but showed a suboptimal correlation with survival or lack of validation, such as the GBC staging system created by Yadav S, et al. [7]. Therefore, new prognostic factors with better predictive capability for BMT patients are needed.

Abnormal lipid metabolism has been reported to play a vital role in tumorigenesis, progression and metastasis through different pathways. For example, abnormal triglyceride metabolism was reported to regulate cell proliferation through AMPK–mTOR pathway, and cholesterol could promote tumor progression and chemotherapy resistance through altering cytoskeleton, angiogenesis and cell apoptosis [8, 9]. Moreover, several lipid parameters were reported to be the efficient prognostic factors of various cancer, such as breast cancer, gastric cancer, hepatocellular carcinoma, etc. [10–12]. However, no study has evaluated the clinical significance and the potential prognostic role of serum lipid profile in MBT patients.

Thus, in the present study, we investigated the prognostic value of serum lipids in BMT, and developed a novel, promising prognostic nomogram based on serum lipid parameters and clinicopathological parameters. Furthermore, we created a new staging system based on the nomogram and validated its efficacy in predicting prognosis in BMT patients treated in a tertiary referral center.

Methods
Patients
All the patients who had documented cases of MBT in the Peking Union Medical College Hospital (PUMCH) database between January 2003 and December 2017 were retrospectively reviewed. Patients were included if they 1) received surgery and histopathologically confirmed MBT; 2) post-surgery follow-up more than 3 months; 3) relatively complete preoperative examination. And patients were excluded if they 1) lack of serum lipids examination; 2) with an AJCC TNM stage of 4; 3) with a history of other malignant tumors.

Data collection and definition
Baseline information including demographic data, history of alcohol and fatty liver, jaundice, tumor condition, therapeutic options, laboratory data, and overall survival (OS) were obtained from medical records. Tumor condition included tumor size, extent, lymph node metastasis, and histopathological data. Therapeutic options included radical cure and palliative resection, of which radical cure was defined as fully clearing of gross lesion, lymphadenectomy, and histologically negative (R0) surgical margin. Blood samples were obtained from all patients after over 12 h overnight fasting, and all samples were immediately transferred to the laboratory for batch analysis. Laboratory data including hepatic parameters (including albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (GGT), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), total bilirubin (TBIL)), serum lipid assessment (including total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), ratio of TC to HDL (TC/HDL), ratio of TG to HDL (TG/HDL), apolipoprotein A-1 (ApoA1), apolipoprotein B (ApoB) and lipoprotein) and CA199 level were obtained at the time of diagnosis of MBT.

Statistical analysis
Descriptive data are expressed as mean ± SD, median (interquartile range, IQR) or frequencies (%), respectively. Normally and non-normally distributed quantitative variables were compared using two-sample t-test and Mann-Whitney U test, respectively. Categorical variables were compared using Fisher’s exact test or Chi-Square test according to sample size. The cutoff value for body mass index (BMI), hepatic parameters and CA199 were defined according to the reference range in
the clinical application. And for serum lipid parameters, the cut-off value was calculated through R package ‘maxstat’, which could divide cohorts into 2 groups with maximum differences of the log-rank test results for overall survival [13].

To identify survival-associated parameters, univariate Cox regression was first performed using R package ‘survival’ in the whole cohort (n = 368) [14]. And ‘timeROC’ package was used to further evaluate the prognostic ability of various serum lipid parameters. Then we performed multivariate COX analysis in the modified cohort (n = 252) which excluded patients with incomplete data of serum lipid, hepatic parameters or CA199 to identified independent prognostic factors. Subsequently, we performed the proportional-hazards assumption test based on Schoenfeld residuals to exclude time-dependent factors. Then we randomly separated the 252 patients into training set (n = 152) and validation set (n = 100) with the ratio of 3:2. And the independent prognostic factors were included to construct a novel prognostic nomogram using the ‘rms’ R package based on the training set [15]. The discriminative ability of the nomogram was evaluated by the Harrell’s concordance index (C-index), time-dependent receiving operating characteristics (ROC) curve. Moreover, calibration plots, integrated discrimination improvement (IDI), decision curve analysis (DCA) were performed to graphically evaluate the consistency and efficacy of the nomogram [16]. Furthermore, the prognostic nomogram was evaluated in the validation set using the same methods.

We further calculated the risk score of each patients based on the nomogram, then constructed a new staging system. To compare the prognostic predictive ability between our nomogram-based staging system and TNM staging system, Kaplan-Meier (K-M) OS curves were constructed to estimate the prognoses of patients, and the survival differences among subgroups were assessed by a two-sided log-rank test. C-indexes of various staging systems were compared using the likelihood-ratio test. All analyses were performed with R version 3.6.3 (The R Foundation for Statistical Computing, Vienna, Austria) and Statistical Package for the Social Sciences (SPSS) software version 26 (SPSS Inc., Chicago, IL, USA), and a two-tailed P-value of < 0.05 was considered statistically significant. Hazard ratios (HRs) and 95% confidence intervals (CIs) were reported if necessary.

**Results**

**Patient characteristics**

A total of 368 patients met the selection criteria were included in this study, with 73 GBC, 74 ICC and 221 ECC. The median age at diagnosis was 62 (IQR, 56–69) years, and 168 patients (45.7%) were female. Besides, the proportion of the patients at TNM stage I, II, III were 36.1, 32.6 and 31.3%, respectively. And 248 patients (67.4%) had R0 surgical margin, with 232 patients (63.0%) received a radical cure. The median overall survival was 20 (IQR, 10.7–36.3) months. Table 1 showed the detailed demographic and clinicopathological features of the cohort. And the median overall survival of the training set (n = 152) and validation set (n = 100) were 18.9 (10.2–34.2) months, 24.9 (11.1–39.4) months, respectively (Additional file 1: Table S1). Besides, in the training set, 35.5% was at TNM stage I, 30.3% at stage II, 34.2% at stage III, and 63.2% of the patients received radical cure. Consistently, in the validation set, 40.0% was at TNM stage I, 27.0% at stage II, 33.0% at stage III, and 61.0% of the patients received radical cure.

**Association between serum lipids and survival time**

The cut-off value of TC, TG, HDL, LDL, TC/HDL, TG/HDL, ApoA1, ApoB and lipoprotein were 7.28 mmol/L, 3.14 mmol/L, 0.95 mmol/L, 1.96 mmol/L, 10.08, 4.16, 1.11 g/L, 0.90 g/L, 72 mg/L, respectively. Then we defined the group with serum lipid parameters higher than the cut-off value as high-risk group, and low-risk group if not. High level of TC, TG, HDL, HDL, ApoB and lipoprotein showed significantly poorer overall survival (Fig 1a-c, e, f, h, i). Besides, HDL and ApoA1 showed significantly better prognosis in the high-risk group when compared with low-risk group (Fig 1d, g). The results of time-dependent ROC curve for OS showed that TC and LDL performed relatively poor predictive performance, while TC/HDL, ApoB and lipoprotein exhibited favorable discriminative ability (Fig. 1j). Especially, lipoprotein presented an obviously better discriminative ability than other parameters after 30 months, ApoB presented a relatively good discriminative capability during 20–30 months, and TC/HDL showed the optimal predictive ability within 20 months after surgery.

**The prognostic factors of patients with MBT**

The unvariable analysis demonstrated that BMI, jaundice, lymph node metastasis, intrahepatic involvement, extrahepatic involvement, tumor differentiation, radical cure, R0, TG, HDL, TC/HDL, TG/HDL, ApoA1, ApoB, lipoprotein, albumin, GGT, ALP, TBIL, CA199 were associated with OS (P < 0.05) (Table 2). We further performed multivariate COX analysis in the training set to identify independent prognostic factors. And lymph node metastasis (P = 5.88 × 10−7), tumor differentiation (P = 0.023), radical cure (P = 4.87 × 10−7), R0 (P = 0.025), TC/HDL (P = 0.049), ApoB (P = 7.12 × 10−7), lipoprotein (P = 1.12 × 10−6), CA199 (P = 0.007) were shown to determine the OS (Table 2). We further performed proportional-hazards assumption test based on Schoenfeld residuals and excluded R0 for it was a time-dependent factor (P < 0.05) (Additional file 2: Figure S1).
### Table 1 Baseline characteristics

| Characteristics                  | n (%)       |
|----------------------------------|-------------|
| Total, N                         | 368 (100)   |
| **Tumor type**                   |             |
| GBC                              | 73 (19.8)   |
| ICC                              | 74 (20.1)   |
| ECC                              | 221 (60.0)  |
| **Age (years)**                  |             |
| ≤ 60                             | 155 (42.1)  |
| > 60                             | 213 (57.9)  |
| **Sex**                          |             |
| Female                           | 168 (45.7)  |
| Male                             | 200 (54.3)  |
| **BMI at diagnosis, kg/m²**      |             |
| < 18.5                           | 19 (5.2)    |
| 18.5–22.9                        | 128 (34.8)  |
| ≥ 23                             | 177 (48.1)  |
| NA                               | 44 (12.0)   |
| **Alcohol**                      |             |
| Yes                              | 90 (24.5)   |
| No                               | 278 (75.5)  |
| **Fatty liver**                  |             |
| Yes                              | 27 (7.3)    |
| No                               | 341 (92.7)  |
| **Jaundice**                     |             |
| Yes                              | 219 (59.5)  |
| No                               | 149 (40.5)  |
| **Tumor size, cm**               |             |
| D ≤ 2                            | 180 (50.6)  |
| 2 < D ≤ 3                        | 85 (23.1)   |
| 3 < D ≤ 4                        | 35 (9.5)    |
| D > 4                            | 56 (15.2)   |
| NA                               | 12 (3.3)    |
| **Lymph node metastasis**        |             |
| Yes                              | 122 (33.2)  |
| No                               | 246 (66.8)  |
| **Extrahepatic involvement**     |             |
| Yes                              | 252 (68.5)  |
| No                               | 116 (31.5)  |
| **Intrahepatic involvement**     |             |
| Yes                              | 111 (30.2)  |
| No                               | 257 (69.8)  |
| **Gallbladder involvement**      |             |
| Yes                              | 91 (24.7)   |
| No                               | 277 (75.3)  |
| **AJCC 8th TNM stage**           |             |
| I                                | 133 (36.1)  |
| II                               | 120 (32.6)  |
| III                              | 115 (31.3)  |
| Tumor differentiation            |             |
| Undifferentiation                | 2 (0.5)     |
| Low                              | 36 (9.8)    |
| Low-moderate                     | 98 (26.6)   |
| Moderate                         | 102 (27.7)  |
| Moderate-high                    | 28 (7.6)    |
| High                             | 102 (27.7)  |
| Radical cure                     |             |
| Yes                              | 232 (63.0)  |
| No                               | 136 (37.0)  |
| TC level, mmol/L                 |             |
| ≤ 7.28                           | 301 (81.8)  |
| > 7.28                           | 67 (18.2)   |
| TG level, mmol/L                 |             |
| ≤ 3.14                           | 301 (81.8)  |
| > 3.14                           | 67 (18.2)   |
| HDL level, mmol/L                |             |
| ≤ 0.95                           | 205 (55.7)  |
| > 0.95                           | 163 (44.3)  |
| LDL level, mmol/L                |             |
| ≤ 1.96                           | 41 (11.1)   |
| > 1.96                           | 327 (88.9)  |
| TC/HDL                           |             |
| ≤ 10.08                          | 256 (69.6)  |
| > 10.08                          | 112 (30.4)  |
| TG/HDL                           |             |
| ≤ 4.16                           | 258 (70.1)  |
| > 4.16                           | 110 (29.9)  |
| ApoA1 level, g/L                 |             |
| ≤ 1.11                           | 166 (45.1)  |
| > 1.11                           | 150 (40.8)  |
| ApoB level, g/L                  |             |
| ≤ 0.90                           | 210 (57.1)  |
| > 0.90                           | 105 (28.5)  |
| Lipoprotein level, mg/L          |             |
| ≤ 72                             | 152 (41.3)  |

### Table 1 Baseline characteristics (Continued)

| Characteristics                  | n (%)       |
|----------------------------------|-------------|
| I                                | 133 (36.1)  |
| II                               | 120 (32.6)  |
| III                              | 115 (31.3)  |
| Tumor differentiation            |             |
| Undifferentiation                | 2 (0.5)     |
| Low                              | 36 (9.8)    |
| Low-moderate                     | 98 (26.6)   |
| Moderate                         | 102 (27.7)  |
| Moderate-high                    | 28 (7.6)    |
| High                             | 102 (27.7)  |
| Radical cure                     |             |
| Yes                              | 232 (63.0)  |
| No                               | 136 (37.0)  |
| TC level, mmol/L                 |             |
| ≤ 7.28                           | 301 (81.8)  |
| > 7.28                           | 67 (18.2)   |
| TG level, mmol/L                 |             |
| ≤ 3.14                           | 301 (81.8)  |
| > 3.14                           | 67 (18.2)   |
| HDL level, mmol/L                |             |
| ≤ 0.95                           | 205 (55.7)  |
| > 0.95                           | 163 (44.3)  |
| LDL level, mmol/L                |             |
| ≤ 1.96                           | 41 (11.1)   |
| > 1.96                           | 327 (88.9)  |
| TC/HDL                           |             |
| ≤ 10.08                          | 256 (69.6)  |
| > 10.08                          | 112 (30.4)  |
| TG/HDL                           |             |
| ≤ 4.16                           | 258 (70.1)  |
| > 4.16                           | 110 (29.9)  |
| ApoA1 level, g/L                 |             |
| ≤ 1.11                           | 166 (45.1)  |
| > 1.11                           | 150 (40.8)  |
| ApoB level, g/L                  |             |
| ≤ 0.90                           | 210 (57.1)  |
| > 0.90                           | 105 (28.5)  |
| Lipoprotein level, mg/L          |             |
| ≤ 72                             | 152 (41.3)  |
Table 1 Baseline characteristics (Continued)

| Characteristics | n (%) |
|-----------------|-------|
| > 72            | 118 (32.1) |
| NA              | 98 (26.6) |
| Albumin level, g/L |       |
| ≤ 35            | 59 (16.0) |
| > 35            | 305 (82.9) |
| NA              | 4 (1.1) |
| ALT level, U/L  |       |
| ≤ 40            | 116 (31.5) |
| > 40            | 252 (68.5) |
| AST level, U/L  |       |
| ≤ 40            | 130 (35.3) |
| > 40            | 233 (63.3) |
| NA              | 5 (1.4) |
| GGT level, U/L  |       |
| ≤ 45            | 72 (19.5) |
| > 45            | 291 (79.1) |
| NA              | 5 (1.4) |
| ALP level, U/L  |       |
| ≤ 135           | 121 (32.9) |
| > 135           | 242 (65.7) |
| NA              | 5 (1.4) |
| LDH level, U/L  |       |
| ≤ 250           | 300 (81.5) |
| > 250           | 61 (16.6) |
| NA              | 7 (1.9) |
| TBIL level, umol/L |     |
| ≤ 17.1          | 113 (30.7) |
| > 17.1          | 255 (69.3) |
| CA199 level, U/mL |       |
| ≤ 37            | 94 (25.5) |
| > 37            | 263 (71.5) |
| NA              | 11 (3.0) |
| Overall survival, months | 219 (11.0–39.0) |

ALP Alkaline phosphatase, ALT Alanine aminotransferase, ApoA1 Apolipoprotein A-1, ApoB Apolipoprotein B, AST Aspartate aminotransferase, BMI Body mass index, CA199 Carbohydrate antigen 199, CC Cholangiocarcinoma, D maximum diameter of tumor, ECC Extrahepatic cholangiocarcinoma, GBC Gallbladder cancer, GGT Gamma-glutamyl transpeptidase, HDL High-density lipoprotein, ICC Intrahepatic cholangiocarcinoma, LDH Lactate dehydrogenase, LDL Low-density lipoprotein, NA Not accessible, R0 Histologically negative surgical margin, TBIL Total bilirubin, TC Total cholesterol, TG Triglycerides

Association among lipid prognostic factors, clinicopathological features and surgical outcome

To better understand the roles of serum lipid in the prognosis of MBT patients, we further analyzed the relationships among the 3 lipid prognostic factors and the clinicopathological characteristics as well as the surgical outcomes of MBT patients (Table 3). Specially, TC/HDL, ApoB and lipoprotein all related to tumor type and jaundice, and not associated with alcohol, fatty liver, cardiovascular diseases, lymph node metastasis, radical cure and blood loss during surgery. Patients with high level of TC/HDL tend to have lower BMI, tumor larger than 4 cm, and more extrahepatic involvement but less intrahepatic involvement, gallbladder involvement and less proportion of high differentiation. What's more, high-level TC/HDL patients might have longer postoperative hospital days, with a higher probability of postoperative bleeding. For patients with a high level of ApoB, they might more likely to be overweight and have hepatic and gallbladder involvement. While high lipoprotein level related to overweight, extrahepatic involvement, more postoperative bleeding and infection.

Construction and validation of a novel nomogram for MBT patients

The prognostic nomogram was then constructed by using the 7 independent prognostic factors previously identified to facilitate clinical prognostic prediction for MBT patients. Figure 2a shows the nomogram predicting the survival probability at 1, 3, and 5 years based on the training set. The C-index of the nomogram for predicting OS was 0.738 (95%CI 0.681–0.795). The AUC values of the 1-, 3-, and 5-year survival predictions using the nomogram were 0.786, 0.846, and 0.878, respectively, indicating a favorable predictive ability (Fig. 2b-d). Besides, when compared to TNM and nomogram-d (nomogram deleted serum lipid parameters, which constructed only based on lymph node metastasis, tumor differentiation, radical cure and CA199), the nomogram presented a higher value of AUC. Consistently, IDI analysis showed adding lipid parameters could significantly improve the discriminative ability of the nomogram (IDI = 0.055, P = 0.002). Moreover, the calibration plots (Fig. 3a-c) showed consistency between the nomogram prediction and actual observation of 1-, 3- and 5-year OS in the training set. And DCA (Fig. 3g-i) indicated favorable efficacy of the novel nomogram when compared to the TNM staging system.

In the validation set, the C-index of the nomogram was 0.721 (95%CI 0.660–0.782), AUC values of the 1-, 3-, and 5-year survival predictions using the nomogram were also better than TNM and nomogram-d (Fig. 2e-g), and adding lipid parameters also significantly improved the integrated discriminative ability of the nomogram (IDI = 0.126, P < 0.001). Also, both the calibration plots and DCA demonstrated favorable performance for predicting 1-, 3- and 5-year OS in the validation set (Fig. 3d-f and j-i).
Comparison between the new staging system and AJCC TNM staging system

According to the novel nomogram, each patient was assigned a risk score which could indicate individual prognosis. Then we classified the whole cohort into low-risk (n = 119), medium-risk (n = 64), and high-risk (n = 69) groups based on score, with cut-off value of "0.00 - 16.49", "16.50 - 24.99", "≥ 25.00", respectively (Fig. 4a). And KM curves suggested significant differences of prognosis among newly defined 3 groups (P < 2.0 × 10^{-16}). While the TNM staging system could not totally separate the prognosis of different TNM stage patients according to the KM OS curves (Fig. 4b). The C-index for the novel staging system was 0.710 (95% CI, 0.670–0.750) compared with 0.588 (95% CI, 0.541–0.634) for the TNM staging system, indicating a better performance in predicting survival (P < 0.001).

To further evaluate the efficacy of novel staging system in clinical application, we performed subgroup analysis based on therapeutic options and tumor types. For
patients received radical cure, the new staging system performed better discriminative and predictive ability than the AJCC TNM staging system (Fig. 4c-d), with the C-index of 0.637 and 0.547, respectively ($P = 0.021$). For patients received palliative resection, the new staging system also showed better performance than the TNM staging system. And the C-index of the new system was 0.643 compared to 0.582 for TNM system ($P < 0.001$) (Fig. 4e-f).

For GBC patients, the novel staging system showed better ability in distinguishing patients at various stages with log-rank $p$-value of survival differences was $7 \times 10^{-8}$ (Fig. 4g). While the TNM staging system could hardly distinguish stage I to stage II according to the KM OS curves (Fig. 4h).

The C-index of the novel staging system and TNM system were 0.711 and 0.713 ($P = 0.258$). Also, the new staging system exhibited a better performance in distinguishing ICC patients in different stages when compared with the AJCC

### Table 2

Univariate and multivariate COX proportional hazards analysis of clinicopathological variables

| Characteristics | Univariate COX analysis (n = 368) | Multivariate COX analysis (n = 252) |
|-----------------|-----------------------------------|-----------------------------------|
|                 | HR (95% CI)                       | $P$ value | HR (95% CI) | $P$ value |
| Age, years ($\geq 60$/> 60) | 1.126(0.860–1.473) | 0.388 | – | – |
| Sex (Female/Male) | 0.963(0.738–1.256) | 0.780 | – | – |
| BMI, kg/m$^2$ (< 18.5/18.5–23/223) | 0.734(0.588–0.916) | 0.006 | 0.913(0.594–1.405) | 0.680 |
| Alcohol (No/Yes) | 1.088(0.803–1.474) | 0.586 | – | – |
| Fatty liver (No/Yes) | 1.211(0.745–1.965) | 0.438 | – | – |
| Jaundice (No/Yes) | 1.547(1.17–2.045) | 0.002 | 1.441(0.709–2.931) | 0.313 |
| Cardiovascular diseases (No/Yes) | 0.966(0.736–1.267) | 0.801 | – | – |
| Tumor size, cm ($\geq 2.2$/3.3–4/$>$ 5) | 1.028(0.913–1.158) | 0.646 | – | – |
| Lymph node metastasis (No/Yes) | 2.301(1.752–3.022) | 2.07e-09 | 2.776(1.860–4.144) | 5.88e-07 |
| Extrahepatic involvement (No/Yes) | 1.398(1.04–1.878) | 0.026 | 1.277(0.614–2.656) | 0.513 |
| Intrahepatic involvement (No/Yes) | 1.386(1.047–1.835) | 0.022 | 1.491(0.944–2.354) | 0.087 |
| Gallbladder involvement (No/Yes) | 1.170(0.861–1.591) | 0.314 | – | – |
| Tumor differentiation (low/low-moderate/moderate/moderate-high/high/undefined) | 0.781(0.705–0.865) | 2.01e-06 | 0.840(0.723–0.977) | 0.023 |
| Radical cure (No/Yes) | 0.381(0.292–0.498) | 1.35e-12 | 0.263(0.174–0.464) | 4.89e-07 |
| R0 (No/Yes) | 0.643 (0.493–0.839) | 0.001 | 1.681(1.069–2.643) | 0.025 |
| TC ($\leq 4.97$/> 4.97) | 0.800(0.552–1.158) | 0.236 | – | – |
| TG ($\leq 0.9$/> 0.9) | 1.477(1.063–2.051) | 0.020 | 1.022(0.456–2.288) | 0.959 |
| HDL ($\leq 0.94$/> 0.94) | 0.676(0.516–0.886) | 0.004 | 1.026(0.611–1.722) | 0.924 |
| LDL ($\leq 2.18$/> 2.18) | 0.790(0.534–1.168) | 0.238 | – | – |
| TC/HDL ($\leq 11.4$/> 11.4) | 1.404(1.061–1.858) | 0.018 | 2.330(1.005–5.404) | 0.049 |
| TG/HDL ($\leq 4.16$/> 4.16) | 1.355(1.022–1.797) | 0.034 | 0.550(0.230–1.314) | 0.178 |
| ApoA1 ($\leq 0.72$/> 0.72) | 0.694(0.520–0.927) | 0.013 | 0.967(0.571–1.636) | 0.900 |
| ApoB ($\leq 0.9$/> 0.9) | 1.368(1.051–1.842) | 0.039 | 2.931(1.916–4.483) | 7.12e-07 |
| Lipoprotein ($\leq 89$/> 89) | 1.630(1.188–2.235) | 0.002 | 2.635(1.784–3.891) | 1.12e-06 |
| Albumin ($\geq 35$/< 35) | 0.965(0.938–0.992) | 0.001 | 1.157(0.686–1.953) | 0.585 |
| ALT ($\leq 40$/> 40) | 1.339(0.995–1.802) | 0.054 | – | – |
| AST ($\geq 40$/> 40) | 1.252(0.941–1.665) | 0.123 | – | – |
| GGT ($\geq 45$/< 45) | 1.968(1.345–2.881) | 4.96e-04 | 0.822(0.444–1.522) | 0.534 |
| ALP ($\geq 135$/< 135) | 1.634(1.211–2.205) | 0.001 | 0.734(0.386–1.397) | 0.346 |
| LDH ($\geq 250$/< 250) | 1.401(0.996–1.971) | 0.052 | – | – |
| TBIL ($\geq 17.1$/< 17.1) | 1.619(1.183–2.216) | 0.002 | 1.311(0.720–2.385) | 0.376 |
| CA199 ($\geq 37$/< 37) | 2.408(1.675–3.463) | 2.12e-06 | 2.043(1.210–3.447) | 0.007 |

All statistical tests were two-sided. Bold type means $P < 0.05$.

*ALP* Alkaline phosphatase, *ALT* Alanine aminotransferase, *ApoA1* ApolipoproteinA-1, *APOB* Apolipoprotein B, *AST* Aspartate aminotransferase, *BMI* Body mass index, *CA199* Carbohydrate antigen 199, *GGT* Gamma-glutamyl transpeptidase, *HDL* High-density lipoprotein, *ICC* Intrahepatic cholangiocarcinoma, *LDH* Lactate dehydrogenase, *LDL* Low-density lipoprotein, *R0* Histologically negative surgical margin, *TBIL* Total bilirubin, *TC* Total cholesterol, *TG* Triglycerides.
Table 3 Association among serum lipids and clinicopathological parameters and surgical outcomes

| Clinicopathological characteristics | TC/HDL < 10.08 (n = 187) | > 10.08 (n = 65) | ApoB, g/L ≤ 0.9 (n = 87) | > 0.9 (n = 165) | Lipoprotein, g/L ≤ 72 (n = 141) | > 72 (n = 111) | p |
|------------------------------------|---------------------------|-----------------|--------------------------|-----------------|-------------------------------|----------------|----|
| Tumor type                         |                           |                 |                          |                 |                               |                 |    |
| GBC                                | 64(34.2)                  | 2(3.1)          | 30(34.5)                 | 36(21.8)        | 32(22.7)                      | 34(30.6)        | 0.004 |
| ICC                                | 42(22.5)                  | 5(7.7)          | 25(28.7)                 | 22(13.3)        | 20(14.2)                      | 27(24.3)        | 0.040 |
| ECC                                | 81(43.3)                  | 58(89.2)        | 32(36.8)                 | 10(64.8)        | 89(63.1)                      | 50(45.0)        | 0.004 |
| BMI ≥ 23 kg/m²                     | 122(65.2)                 | 3(4.6)          | 57(65.5)                 | 68(41.2)        | 59(41.8)                      | 66(59.5)        | 0.005 |
| Alcohol                            | 40(21.4)                  | 21(32.3)        | 17(19.5)                 | 44(26.7)        | 32(22.7)                      | 29(26.1)        | 0.528 |
| Fatty liver                        | 8(4.3)                    | 5(7.7)          | 2(2.3)                   | 11(6.7)         | 9(6.4)                        | 4(3.6)          | 0.322 |
| Jaundice                           | 69(36.9)                  | 64(98.5)        | 32(36.8)                 | 101(61.2)       | 87(61.7)                      | 46(41.4)        | 0.001 |
| Cardiovascular disease             | 77(41.2)                  | 25(38.5)        | 33(38.0)                 | 69(41.8)        | 57(40.4)                      | 45(40.5)        | 0.985 |
| Tumor size, cm                     | 0.029                     |                 | 0.882                    |                 |                               |                 |    |
| d ≤ 2                              | 78(41.7)                  | 34(52.3)        | 35(40.2)                 | 77(46.7)        | 68(48.2)                      | 44(39.6)        | 0.173 |
| 2 < d ≤ 3                          | 40(21.4)                  | 19(29.2)        | 21(24.1)                 | 38(23.0)        | 32(22.7)                      | 27(24.3)        | 0.762 |
| 3 < d ≤ 4                          | 21(11.2)                  | 6(9.2)          | 10(11.5)                 | 17(10.3)        | 15(10.6)                      | 12(10.8)        | 0.965 |
| d > 4                              | 40(21.4)                  | 46(2.2)         | 16(18.4)                 | 28(17.3)        | 22(15.6)                      | 22(19.8)        | 0.381 |
| Lymph node metastasis              | 58(31.0)                  | 23(35.4)        | 25(28.7)                 | 56(33.9)        | 42(29.8)                      | 39(35.1)        | 0.367 |
| Extrahepatic involvement           | 96(51.3)                  | 62(95.4)        | 42(48.3)                 | 116(70.3)       | 100(70.9)                     | 58(52.3)        | 0.002 |
| Intrahepatic involvement           | 67(35.8)                  | 14(21.5)        | 35(40.2)                 | 46(27.9)        | 40(28.4)                      | 41(36.9)        | 0.148 |
| Gallbladder involvement            | 69(36.9)                  | 9(13.8)         | 36(41.4)                 | 42(25.5)        | 39(27.7)                      | 39(35.1)        | 0.203 |
| TNM                                |                           |                 |                          |                 |                               |                 |    |
| I                                  | 69(36.9)                  | 25(38.5)        | 32(36.8)                 | 62(37.6)        | 52(36.9)                      | 42(37.8)        | 0.876 |
| II                                 | 43(23.0)                  | 30(46.2)        | 17(19.5)                 | 56(33.9)        | 47(33.3)                      | 26(23.4)        | 0.085 |
| III                                | 75(40.1)                  | 10(15.4)        | 38(43.7)                 | 47(28.5)        | 42(29.8)                      | 43(38.7)        | 0.136 |
| High differentiation               | 62(33.2)                  | 13(20.0)        | 25(28.7)                 | 50(30.3)        | 39(27.7)                      | 36(32.4)        | 0.411 |
| Radical cure                       | 119(63.6)                 | 38(58.5)        | 59(67.8)                 | 98(59.4)        | 90(63.8)                      | 67(60.4)        | 0.573 |
| RD                                 | 120(64.2)                 | 39(60.0)        | 25(60.0)                 | 99(60.0)        | 91(64.5)                      | 68(61.3)        | 0.592 |
| CA199 > 37 U/mL                    | 113(60.4)                 | 60(92.3)        | 58(66.7)                 | 115(69.7)       | 107(75.9)                     | 66(59.5)        | < 0.001 |

Bold type means P < 0.05

ApoB Apolipoprotein B, BMI Body mass index, CA199 Carbohydrate antigen 199, CC Cholangiocarcinoma, ECC Extrahepatic cholangiocarcinoma, GBC Gallbladder cancer, ICC Intrahepatic cholangiocarcinoma, TC Total cholesterol

Estimated blood loss and postoperative days were expressed as median (interquartile range, IQR)
TNM staging system (Fig. 4i-j). The C-index for the new staging system and TNM staging system were 0.721 and 0.684 ($P = 0.203$). As for ECC patients, the new staging system showed a better discriminative and predictive ability than the TNM system, with the C-index of 0.696 and 0.506, respectively ($P = 1.70 \times 10^{-7}$).
Fig. 3 (See legend on next page)
(See figure on previous page.)

**Fig. 3** Calibration curves and decision curve analysis of the nomogram. Calibration curves for predicting survival at 1, 3, and 5 years in the training cohort (a-c) and validation cohort (d-f). The X-axis indicates the nomogram-predicted probability, and the y-axis indicates actual survival. Time-dependent decision curve analysis for the clinical benefit of the nomograms and the corresponding scope of application in the training set (g-i) and validation set (j-l). The grey solid line represents the assumption that all patients survive in the first, third, and fifth year. The black solid line represents the assumption that no patients survive in the first, third, and fifth year. Nomogram-d was constructed without serum lipid parameters, which only based on lymph node metastasis, tumor differentiation, radical cure and CA199.

**Fig. 4** Comparing discriminative ability of two staging system through K-M curves. Overall survival of patients with MBT classified by the new clinical staging system (a) and AJCC TNM staging system (b) in total cohort; and the 2 systems in radical cure cohort (c, d), palliative cohort (e, f), GBC cohort (g, h), ICC cohort (i, j), and ECC cohort (k, l). K-M, Kaplan-Meier; MBT, malignant biliary tumor; GBC, gall bladder cancer; ICC, intrahepatic cholangiocarcinoma; ECC, extrahepatic cholangiocarcinoma.
Discussion
Lipid metabolism gradually become a major trend in cancer research, researchers have found that lipid metabolism is reprogrammed in cancer cells, and certain lipids and their derivatives accumulate in the tumor microenvironment, which may promote cell migration and invasion. While the role of lipids in MBT remains unclear [17]. To the best of our knowledge, this is the first research found a high level of TC/HDL, ApoB and lipoprotein were associated with poor prognosis in MBT patients. And based on these 3 lipid parameters and several clinicopathological factors, we constructed a novel prognostic nomogram and a staging system which showed favorable discriminative and predictive ability. Besides, the novel staging system presented a better discriminative ability in predicting the OS than the AJCC TNM staging system in MBT cohort, which could be a great complement to the TNM staging system.

Aberrant lipid metabolism is gradually recognized as an important underlying mechanism of tumorigenesis and increasingly studies suggested that lipid and their metabolism were associated with the risk and the prognosis of cancer [9]. Since the hepatobiliary system performs a vital role in several processes of lipid transport and metabolism, it raised the question that whether lipids involved in the progression and metastasis of biliary tract cancer, and whether lipids parameters could be a new and convenient biomarker for prognosis. In our study, we revealed that TC/HDL, ApoB and lipoprotein could independently predict BMT prognosis, and these parameters could be easily measured in routine clinical laboratories and show promising diagnostic accuracy for prognosis.

Cholesterol, acts as a membrane constituent, is closely associated with membrane biosynthesis of cell proliferation. What’s more, cholesterol itself, as well as its metabolites, could regulate multiple signaling pathways of tumorigenesis, such as promoting cell proliferation by modulating hedgehog signaling proteins [18], inhibiting immune-effector cells by regulating LXR signaling [17], etc. Besides, TC/HDL was reported to be a surrogate marker of insulin resistance [19], which could further activate oncogene expression through insulin-IGF-1/IGFBP pathway [20], thus promoting tumorigenesis. Consistently, our study found that high-level TC/HDL associated with a poor prognosis. Also previous studies suggested that reduced HDL and increased cholesterol were associated with poor prognosis of cancer [10, 21]. Whether the prognostic value of the ratio of TC to HDL better than TC or HDL could be further investigated in large-scale cohorts or other cancers.

ApoB, as a ligand of LDL receptor, plays an important role in transferring lipids, participating lipoprotein metabolism and involving in tumorigenesis [22, 23], which could partially explain the association between high-level ApoB and poor MBT prognosis. Also, consistent with our results, Borgquist S, et al. reported high ApoB was associated with cancer risk in colorectal cancer, lung cancer and breast cancer in a cohort of 28,098 patients [22]. And Yan X, et al. found high-level ApoB could predict poor post-surgery prognosis in hepatocellular carcinoma [24].

While lipoprotein is a biochemical assembly of lipid and protein, which provides an efficient system for transporting lipid and regulating cellular cholesterol hemostasis. Though several subclasses of lipoprotein have been reported to be related to carcinogenesis, no study has mentioned the role of lipoprotein in cancer prognosis. Our study proved that lipoprotein could independently predict OS of MBT patients, which probably inspired more studies on the role of lipoprotein in tumorigenesis and prognosis.

What’s more, ApoB and lipoprotein were usually recognized as vital risk factor of cardiovascular diseases, and positively associated with acute myocardial infarction (AMI) and cerebral infarction (CI) [25, 26]. Thus the baseline cardiovascular disease condition and patients died from AMI and CI might introduce confounding bias and affect the accuracy of the results. Thus we also performed univariate and multivariate COX regression analysis of cardiovascular disease condition, which proved that cardiovascular disease did not interfere with the prognosis in biliary tract cancer patients. But surprisingly, we found the level of TC/HDL, ApoB and lipoprotein are not associated with cardiovascular disease in our study, which were contrast to previous studies [26, 27]. And different cut-off values of ApoB and lipoprotein among these studies might partially explain the inconsistency. Besides, our cohort is a biliary tract cancer cohort, cancer itself and multiple factors like races, could affect serum lipid levels [9].

The novel MBT prognostic nomogram first integrated serum lipid parameters in addition to biological parameters like CA199, pathological parameters like tumor differentiation and lymph node metastasis, surgical parameters like the radical cure, which suggested favorable discriminative and predictive ability. Moreover, adding lipid parameters could significantly improve the predictive accuracy and discriminative ability, which further identified by ROC curves, IDI analysis and DCA. Besides, when compared with the TNM system, this nomogram also performed better predictive performance and could distinguish patients with different risks in subgroups of various tumor types or therapeutic options. Thus, the new nomogram and staging system provide a convenient and intuitive tool to initially classify MBT patients into different prognostic stage.
There are limitations in this study. First, given it was a retrospective observational study, clinicopathological information was inevitably limited. Second, the heterogeneity of the study object is relatively large, which might attenuate the strength of evidence. However, we performed subgroup analyses to identify the performance of the novel staging system in GBC, ICC, ECC patients, which may compensate for this problem to some extent. Third, the death caused by AMI, CI or other diseases instead of cancer could introduce confounding bias which may affect the accuracy of our results, which might need detailed patients information and further study. Forth, this study only performed internal validation. To identify whether the nomogram is generalized to other institutes, external validation should be performed if possible. Fifth, this study was a single-center study, which could introduce selection bias, further large-scale multicenter prospective study is needed.

Conclusion
A novel, serum lipid profile based nomogram for MBT patients was successfully constructed, providing new insight into the crosstalk among serum lipids and BMT prognosis. Also the nomogram could facilitate predicting prognosis and guiding individualized treatment. Besides, we established a new staging system to predict prognosis and showed favorable discriminative ability, which would be a great complement to the TNM staging system.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12885-020-07496-8.

Additional file 1: Table S1. Demographic and clinicopathological characteristics of modified training set and validation set.

Additional file 2: Figure S1. Schoenfeld residuals versus ranked survival time for selected predictors. The X-axis represents the survival time, while the Beta values referring to TC/HDL (a), ApoB (b), lipoprotein (c), CA199 (d), tumor differentiation (e), radical cure (f), R0 (g), and lymph node metastasis (h) are shown on the Y-axis. TC, total cholesterol; HDL, high-density lipoprotein; ApoB, apolipoprotein B; CA199: carbohydrate antigen 199.

Abbreviations
ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; ApoA1: Apolipoprotein A-1; ApoB: Apolipoprotein B; AST: Aspartate aminotransferase; BMI: Body mass index; CA199: Carbohydrate antigen 199; CC: Cholangiocarcinoma; CI: Confidence interval; C-index: Harrell’s concordance index; DCA: Decision curve analysis; ECC: Extrahepatic cholangiocarcinoma; GBC: Gallbladder cancer; GGT: Gamma-glutamyl transpeptidase; HDL: High-density lipoprotein; ICC: Intrahepatic cholangiocarcinoma; IDI: Integrated discrimination improvement; IQR: Interquartile range; LDH: Lactate dehydrogenase; LDL: Low-density lipoprotein; MBT: Malignant biliary tumor; OS: Overall survival; PUMCH: Peking Union Medical College Hospital; R0: Histologically negative surgical margin; ROC: Time-dependent receiving operating characteristics; TBIL: Total bilirubin; TC: Total cholesterol; TG: Triglycerides

Acknowledgements
Not applicable.

Authors’ contributions
LS and YM contributed conception and design of the study. XJ performed data analysis, DW, AG, YX, HK, SD, YX and HZ performed the data collection and curation. XL, XS, XZ, HY analyzed and interpreted the results. LS and XJ drafted and reviewed the manuscript. All authors read and approved the final manuscript.

Funding
This work was supported by grants from CAMS Innovation Fund for Medical Sciences (CIFMS) (No.2016-I2M-1-001) and Tsinghua University-Peking Union Medical College Hospital Cooperation Project (PTQH201904552).

Availability of data and materials
Data are available from the corresponding author upon reasonable request.

Ethics approval and consent to participate
All procedures involving human participants were performed in accordance with the ethical standards of the Institutional Ethics Committee of Peking Union Medical College Hospital at the Chinese Academy of Medical Sciences & Peking Union Medical College (ID: S-K1110) and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Given it was a retrospective study, written informed consent was waived.

Consent for publication
Not applicable.

Competing interests
The authors disclose no conflicts.

Author details
1Department of Liver Surgery, Peking Union Medical College Hospital, PUMC & Chinese Academy of Medical Sciences, Beijing 100730, China. 2Peking Union Medical College (PUMC), PUMC & Chinese Academy of Medical Sciences, Beijing 100730, China.

Received: 17 July 2020 Accepted: 5 October 2020
Published online: 09 October 2020

References
1. Cereda S, Belli C, Reni M. Adjuvant treatment in biliary tract cancer: to treat or not to treat? World J Gastroenterol. 2012;18(21):2591–6.
2. Heron DE, Stein DE, Etchelman DJ, Topham AK, Waterman FM, Rosato EL, Alden M, Anne PR. Cholangiocarcinoma: the impact of tumor location and treatment strategy on outcome. Am J Clin Oncol. 2003;26(4):422–8.
3. Gorgen A, Goldaracena N, Zhang W, Sapisochin G. Intrahepatic cholangiocarcinoma, are we making progress? Hepatobiliary Surg Nutr. 2018;7(2):127–9.
4. Blechacz B, Komuta M, Roskams T, Goros GJ. Clinical diagnosis and staging of cholangiocarcinoma. J Gastroenterol. 2011;80(5):1212–22.
5. Chen M, Lin J, Gao J, Zhu H, Zhang B, Wu A, Cai X. Development and validation of a nomogram for survival benefit of lymphadenectomy in resected gallbladder cancer. Hepatobiliary Surg Nutr. 2019;8(5):480–9.
6. Chun YS, Pavlik TM, Vautehy JN. 8th edition of the AJCC Cancer staging manual pancreas and Hepatobiliary cancers. Ann Surg Oncol. 2018;25(4):845–7.
7. Yadav S, Tella SH, Kormalapatla A, Mara K, Prasai K, Mady MH, Hassan M, Smoot RL, Cleary SP, Truty MJ, et al. A novel clinically based staging system for gallbladder Cancer. J Natl Compr Cancer Netw. 2020;18(2):151–9.
8. Xie H, Heier C, Khan B, Vesely PW, Tang Z, Seif V, Schoswolh G, Streng-Bina I, Hoeller G, Ziechner R, et al. Adipose triglyceride lipase activity regulates cancer cell proliferation via AMP-kinase and mTOR signaling. Biochim Biophys Acta Mol Cell Biol Lipids. 2020;1865:158737.
9. Huang C, Freter C. Lipid metabolism, apoptosis and cancer therapy. Int J Mol Sci. 2015;16(1):924–49.
10. Li X, Tang H, Wang J, Xie X, Liu P, Kong Y, Ye F, Shuang Z, Xie Z, Xie X. The effect of preoperative serum triglycerides and high-density lipoprotein-cholesterol levels on the prognosis of breast cancer. Breast. 2017;32:1–6.
11. Jiang S-S, Weng D-S, Jiang L, Zhang Y-J, Pan K, Pan Q-Z, Chen C-L, Zhao J-J, Zhang X-F, Zhang H-X, et al. The clinical significance of preoperative serum cholesterol and high-density lipoprotein-cholesterol levels in hepatocellular carcinoma. J Cancer. 2016;7(6):626–32.
12. Liu BZ, Tao L, Chen YZ, Li XZ, Dong YL, Ma YJ, Li SG, Li F, Zhang WJ. Preoperative body mass index, blood albumin and triglycerides predict survival for patients with gastric cancer. PLoS One. 2016;11(6):e0157401.

13. Hothorn T, Zeileis A. Generalized maximally selected statistics. Biometrics. 2008;64(4):1263–9.

14. Linden A, Yamold PR. Modeling time-to-event (survival) data using classification tree analysis. J Eval Clin Pract. 2017;23(6):1299–308.

15. Qian Z, Li Y, Fan X, Zhang C, Wang Y, Jiang T, Liu X. Prognostic value of a microRNA signature as a novel biomarker in patients with lower-grade gliomas. J Neuro-Oncol. 2018;137(1):127–37.

16. Alba AC, Agoritsas T, Walsh M, Hanna S, Devereaux PJ, McGinn T, Guyatt G. Discrimination and calibration of clinical prediction models: users’ guides to the medical literature. JAMA. 2017;318(14):1377–84.

17. Huang B, Song B, Xu C. Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities. Nat Metabol. 2020;2(2):32–41.

18. Xiao X, Tang JJ, Peng C, Wang Y, Fu L, Qiu ZP, Xiong Y, Yang LF, Cui HW, He XL, et al. Cholesterol Modification of Smoothened Is Required for Hedgehog Signaling. Mol Cell. 2017;66(1):154–162.e110.

19. McLaughlin T, Reaven G, Abbasi F, Lamendola C, Saad M, Waters D, Simon J, Krauss RM. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am J Cardiol. 2005;96(3):399–404.

20. Desbois-Mouthon C, Cadoret A, Blivet-Van Egghelpoel MJ, Bertrand F, Cherqui G, Peret C, Capeau J. Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation. Oncogene. 2001;20(2):252–9.

21. Chen S, Li X, Wen X, Peng S, Xue N, Xing S, Liu Y. Prognostic nomogram integrated baseline serum lipids for patients with non-esophageal squamous cell carcinoma. Ann Transl Med. 2019;7(20):548.

22. Borgquist S, Butt T, Almgren P, Shiffman D, Stocks T, Öhno-Melander M, Manjer J, Melander O. Apolipoproteins, lipids and risk of cancer. Int J Cancer. 2016;138(11):2648–56.

23. Yamakawa S, Bakaeva ME, Ferrell LD, Fan J, Arnold KS, Taylor S, Taylor JM, Innerarity TL. Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals. Proc Natl Acad Sci U S A. 1995;92(18):8483–7.

24. Yan X, Yao M, Wen X, Zhu Y, Zhao H, Qian X, Chen X, Lu W, Lv Q, Zhang L, et al. Elevated apolipoprotein B predicts poor postsurgery prognosis in patients with hepatocellular carcinoma. Onco Targets Ther. 2019;12:1957–64.

25. O'Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, Rangarajan S, Islam S, Pais P, McQueen MJ, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376(9735):212–23.

26. McQueen MJ, Hawken S, Ounpuu S, Sniderman A, Probstfield J, Styn K, Sanderson JE, Hasani M, Volpova E, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008;372(9634):224–33.

27. Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, LaRosa JC, Waters DD, DeMicco DA, Simes RJ, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol. 2014;64(5):485–94.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.